Supplementary Figure Legend

Fig. S1: Subpopulations of $CD4^+$T lymphocytes of the cannabidiol group compared with the placebo group at baseline (day 2), day 8, week 4 and week 12. Subpopulations of $CD4^+$T lymphocytes are presented in column scatter plots. The mean and standard deviation (SD) are expressed with horizontal and vertical bars, respectively. *Indicates p-value < 0.05. CD, cluster of differentiation; D, day; Tcm, T central memory; Tem, T effector memory; Temra, T effector memory RA; Tn, T naive; W, week.

Fig. S2: Subpopulations of $CD8^+$T lymphocytes of the cannabidiol group compared with the placebo group at baseline (day 2), day 8, week 4 and week 12. Subpopulations of $CD8^+$T lymphocytes are presented in column scatter plots. The mean and standard deviation (SD) are expressed with horizontal and vertical bars, respectively. *Indicates p-value < 0.05; **Indicates p-value < 0.01. CD, cluster of differentiation; D, day; Tcm, T central memory; Tem, T effector memory; Temra, T effector memory RA; Tn, T naive; W, week.

Fig. S3: Participants' CBD blood concentrations among treatment groups (adapted with permission from Mongeau-Pérusse et al., 2021(33)). Minimum, 1st quartile, median, 3rd quartile and maximum values are illustrated with box-whisker plots. Mean and outlier values are illustrated with diamonds and circles, respectively. CBD, cannabidiol; D, day; W, week.


Placebo
Cannabidiol
CD25+ CD4+T
p = 0.007**
CD69+ CD4+T
p = 0.400
CD134+ CD4+T
p = 0.570
CD137+ CD4+T
p = 0.189
CD278+ CD4+T
p = 0.042*
CD4+T Cells (%)
CD4+Tn
p = 0.603
CD25+ CD4+Tn
p = 0.020*
CD69+ CD4+Tn
p = 0.166
CD134+ CD4+Tn
p = 0.100
CD137+ CD4+Tn
p = 0.822
CD278+ CD4+Tn
p = 0.953
CD4+Tn Cells (%)
CD4+Tem
p = 0.373
CD25+ CD4+Tem
p = 0.014*
CD69+ CD4+Tem
p = 0.416
CD134+ CD4+Tem
p = 0.634
CD137+ CD4+Tem
p = 0.866
CD278+ CD4+Tem
p = 0.300
CD4+Tem Cells (%)
CD4+Tcm
p = 0.473
CD25+ CD4+Tcm
p = 0.086
CD69+ CD4+Tcm
p = 0.356
CD134+ CD4+Tcm
p = 0.203
CD137+ CD4+Tcm
p = 0.835
CD278+ CD4+Tcm
p = 0.732
CD4+Tcm Cells (%)
CD4+Temra
p = 0.673
CD25+ CD4+Temra
p = 0.009**
CD69+ CD4+Temra
p = 0.600
CD134+ CD4+Temra
p = 0.927
CD137+ CD4+Temra
p = 0.835
CD278+ CD4+Temra
p = 0.298
CD4+Temra Cells (%)
D2
D8
W4
W12


Placebo
Cannabidiol
CD25+ CD8+T
p = 0.894
CD69+ CD8+T
p = 0.408
CD134+ CD8+T
p = 0.954
CD137+ CD8+T
p = 0.001**
CD278+ CD8+T
p = 0.052
CD8+Tn
p = 0.135
CD25+ CD8+Tn
p = 0.568
CD69+ CD8+Tn
p = 0.819
CD134+ CD8+Tn
p = 0.911
CD137+ CD8+Tn
p = 0.336
CD278+ CD8+Tn
p = 0.573
CD8+Tem
p = 0.007*
CD25+ CD8+Tem
p = 0.670
CD69+ CD8+Tem
p = 0.321
CD134+ CD8+Tem
p = 0.305
CD137+ CD8+Tem
p = 0.146
CD278+ CD8+Tem
p = 0.938
CD8+Tcm
p = 0.925
CD25+ CD8+Tcm
p = 0.420
CD69+ CD8+Tcm
p = 0.501
CD134+ CD8+Tcm
p = 0.974
CD137+ CD8+Tcm
p = 0.106
CD278+ CD8+Tcm
p = 0.321
CD8+Temra
p = 0.263
CD25+ CD8+Temra
p = 0.159
CD69+ CD8+Temra
p = 0.541
CD134+ CD8+Temra
p = 0.783
CD137+ CD8+Temra
p = 0.016*
CD278+ CD8+Temra
p = 0.657
D2
D8
W4
W12


700
600
500
400
300
200
100
0
CBD
Placebo
CBD concentration (ng/mL)
D8
W4
W12
Time points

Table S1. List of monoclonal antibodies.

Marker	Clone	Fluorochrome	Company
CD3	UCHT1	BUV395	BD Biosciences
CD3	UCHT1	APC-R700	BD Biosciences
CD3	UCHT1	FITC	BD Biosciences
CD4	RPA-T4	FITC	BD Biosciences
CD8	SK1	APC-H7	BD Biosciences
CD11b	ICRF44	APC-Cy7	BD Biosciences
CD11b	ICRF44	V450	BD Biosciences
CD11c	B-ly6	V450	BD Biosciences
CD14	M5E2	PerCPCy5.5	BD Biosciences
CD14	M5E2	FITC	BD Biosciences
CD16	3G8	PE-CF594	BD Biosciences
CD19	HIB21	PE	BD Biosciences
CD19	HIB21	PerCPCy5.5	BD Biosciences
CD20	2H7	APC-H7	BD Biosciences
CD24	ML5	PE-Cy7	BD Biosciences
CD25	NCAM16.2	APC-R700	BD Biosciences
CD27	M-T271	Alexa Fluor 700	BD Biosciences
CD33	WM53	APC	BD Biosciences
CD38	HIT2	PE	BD Biosciences
CD43	1G10	APC	BD Biosciences
CD45RA	HI100	PerCPCy5.5	BD Biosciences
CD56	NCAM16.2	FITC	BD Biosciences
CD62L	DREG-56	BV421	BD Biosciences
CD69	FN50	BV786	BD Biosciences
CD134	ACT35	PE-CF594	BD Biosciences
CD137	4B4-1	APC	BD Biosciences
CD278	DX29	PE	BD Biosciences
HLA-DR	G46-6	PE-Cy7	BD Biosciences
IgD	IA6-2	PE-CF594	BD Biosciences

CD, cluster of differentiation; HLA-DR, human leukocyte antigene-DR isotype; Ig, immunoglobulin.

Table S2. Peripheral soluble cytokines and chemokines receptors used.

Chemokine Panel 1	Proinflammatory Panel 1	Cytokine Panel 1
MIP-1β	IL-6	IL-16
MDC		VEGF-A

MDC, macrophage derived chemokine; MIP-1β, macrophage inflammatory protein-1β; IL, interleukine; VEGF-A, vascular endothelial growth factor-A.

Table S3. Cytokine results.

Outcomes	Parameters	Estimate	Standard Error	Wald Chi square	p	Effect size
IL-6	Intercept	-0.490	0.685	0.511	0.475	
	Treatment	-0.392	0.165	5.674	**0.017**	0.347
	Baseline	-0.993	0.095	108.968	**0.000**	
	SDS score	0.045	0.041	1.211	0.271	
	Sex	-0.341	0.238	2.054	0.152	
	Age	0.005	0.009	0.343	0.558	
IL-16	Intercept	-180.902	56.445	10.272	**0.001**	
	Treatment	2.448	17.133	0.020	0.886	0.021
	Baseline	-1.015	0.044	543.877	**0.000**	
	SDS score	2.507	3.439	0.531	0.466	
	Sex	19.886	20.454	0.945	0.331	
	Age	1.754	0.639	7.535	**0.006**	
MIP-1β	Intercept	-87.314	24.840	12.356	**0.000**	
	Treatment	13.746	7.565	3.301	0.069	0.265
	Baseline	-0.608	0.117	27.062	**0.000**	
	SDS score	1.865	1.298	2.065	0.151	
	Sex	8.002	11.870	0.454	0.500	
	Age	0.270	0.321	0.704	0.401	
MDC	Intercept	-1404.405	291.097	23.276	**0.000**	
	Treatment	65.980	70.328	0.880	0.348	0.137
	Baseline	-0.611	0.091	44.589	**0.000**	
	SDS score	-3.439	14.564	0.056	0.813	
	Sex	76.750	89.650	0.733	0.392	
	Age	12.242	2.954	17.174	**0.000**	
VEGF-A	Intercept	-48.964	34.636	1.998	0.157	
	Treatment	-14.417	6.722	4.600	**0.032**	0.313
	Baseline	-0.567	0.163	12.130	**0.000**	
	SDS score	0.000	1.245	0.000	1.000	
	Sex	-6.442	11.633	0.307	0.580	
	Age	0.390	0.343	1.293	0.255	

IL, interleukin; MDC, macrophage derived chemokine; MIP-1β, macrophage inflammatory protein-1β; p, p-value; SDS, severity of dependence scale; VEGF-A, vascular endothelial growth factor-A.

Table S4. Monocyte results.

Outcomes	Parameters	Estimate	Standard Error	Wald Chi square	p	Effect size
Total monocytes $CD11c^+$	Intercept	-13.858	7.572	3.349	0.067	
	Treatment	-1.547	1.682	0.845	0.358	0.134
	Baseline	-0.726	0.105	47.605	**0.000**	
	SDS score	0.362	0.317	1.304	0.254	
	Sex	-0.829	2.316	0.128	0.720	
	Age	0.078	0.082	0.906	0.341	
Classical monocytes	Intercept	-10.500	5.933	3.132	0.077	
($CD14^+CD16^-$)	Treatment	-1.460	1.677	0.758	0.384	0.127
	Baseline	-0.713	0.107	44.428	**0.000**	
	SDS score	0.275	0.276	0.991	0.319	
	Sex	-1.126	1.891	0.355	0.551	
	Age	0.063	0.070	0.794	0.373	
Intermediate monocytes	Intercept	-0.032	1.036	0.001	0.975	
($CD14^+CD16^+$)	Treatment	-0.468	0.207	5.082	**0.024**	0.330
	Baseline	-0.552	0.122	20.371	**0.000**	
	SDS score	0.055	0.060	0.852	0.356	
	Sex	-0.081	0.288	0.078	0.780	
	Age	-0.017	0.010	2.644	0.104	
Non-classical monocytes	Intercept	-0.962	0.358	7.230	**0.007**	
($CD14^{lo}CD16^+$)	Treatment	0.127	0.099	1.659	0.198	0.187
	Baseline	-0.896	0.022	1687.591	**0.000**	
	SDS score	0.045	0.023	3.795	0.051	
	Sex	0.049	0.124	0.153	0.696	
	Age	0.005	0.004	1.366	0.242	
DC	Intercept	-2.485	0.981	6.418	**0.011**	
	Treatment	0.170	0.248	0.469	0.493	0.100
	Baseline	-0.769	0.084	83.387	**0.000**	
	SDS score	0.043	0.052	0.691	0.406	
	Sex	-0.098	0.383	0.066	0.798	
	Age	0.018	0.012	2.253	0.133	
mDC	Intercept	-2.578	0.960	7.204	**0.007**	
	Treatment	0.337	0.231	2.127	0.145	0.213
	Baseline	-0.774	0.102	57.113	**0.000**	
	SDS score	0.019	0.043	0.204	0.652	
	Sex	0.351	0.258	1.842	0.175	
	Age	0.018	0.012	2.122	0.145	
mMDSC	Intercept	0.316	0.303	1.085	0.298	
	Treatment	-0.026	0.123	0.045	0.833	0.031
	Baseline	-0.403	0.196	4.216	**0.040**	
	SDS score	0.011	0.017	0.406	0.524	
	Sex	-0.149	0.209	0.507	0.476	
	Age	-0.010	0.004	6.465	**0.011**	
gMDSC	Intercept	0.334	0.762	0.193	0.661	
	Treatment	0.030	0.128	0.053	0.818	0.034
	Baseline	-0.766	0.135	32.037	**0.000**	
	SDS score	0.022	0.026	0.681	0.409	
	Sex	-0.320	0.253	1.599	0.206	
	Age	-0.011	0.007	2.579	0.108	

CD, cluster of differentiation; DC, dendritic cells; gMDSC, granulocytic myeloid derived suppressor cells; mDC, myeloid dendritic cells; mMDSC, monocytic myeloid derived suppressor cells; p, p-value; SDS, severity of dependence scale.

Table S5. Lymphocyte results.

Outcomes	Parameters	Estimate	Standard Error	Wald Chi square	p	Effect size
Total NK	Intercept	-4.794	3.029	2.505	0.113	
	Treatment	-1.003	0.698	2.062	0.151	0.210
	Baseline	-0.774	0.124	38.949	**0.000**	
	SDS score	0.125	0.154	0.660	0.417	
	Sex	0.916	0.805	1.297	0.255	
	Age	0.015	0.034	0.194	0.660	
NK $CD56^{dim}CD16^{hi}$	Intercept	-3.435	2.583	1.768	0.184	
	Treatment	-0.254	0.618	0.168	0.681	0.060
	Baseline	-0.899	0.145	38.184	**0.000**	
	SDS score	0.064	0.147	0.186	0.666	
	Sex	0.930	0.677	1.888	0.169	
	Age	0.010	0.025	0.165	0.685	
NK $CD56^{hi}CD16^{neg}$	Intercept	-0.351	0.209	2.818	0.093	
	Treatment	0.088	0.052	2.804	0.094	0.247
	Baseline	-0.502	0.134	14.143	**0.000**	
	SDS score	-0.016	0.011	2.226	0.136	
	Sex	0.090	0.050	3.282	0.070	
	Age	0.004	0.003	2.296	0.130	
NK $CD56^{neg}CD16^{hi}$	Intercept	-0.899	0.817	1.211	0.271	
	Treatment	-0.736	0.167	19.552	**0.000**	0.643
	Baseline	-0.430	0.072	35.759	**0.000**	
	SDS score	0.033	0.030	1.169	0.280	
	Sex	0.058	0.208	1.169	0.782	
	Age	0.003	0.012	0.064	0.800	
Total B cells	Intercept	-2.136	2.534	0.711	0.399	
	Treatment	-0.490	0.579	0.716	0.397	0.123
	Baseline	-0.457	0.069	44.359	**0.000**	
	SDS score	-0.015	0.100	0.023	0.879	
	Sex	-1.245	0.701	3.155	0.076	
	Age	-0.004	0.032	0.014	0.906	
Early B cells	Intercept	-7.950	4.807	2.735	0.098	
	Treatment	-2.010	1.329	2.287	0.130	0.221
	Baseline	-0.875	0.056	241.367	**0.000**	
	SDS score	0.156	0.230	0.462	0.497	
	Sex	-1.025	1.373	0.557	0.455	
	Age	-0.013	0.036	0.130	0.719	
Late B cells	Intercept	-4.250	4.050	1.101	0.294	
	Treatment	2.088	1.313	2.529	0.112	0.232
	Baseline	-0.874	0.056	245.400	**0.000**	
	SDS score	-0.159	0.233	0.469	0.494	
	Sex	1.055	1.342	0.617	0.432	
	Age	0.007	0.035	0.043	0.835	
Total T cells	Intercept	-10.539	10.037	1.103	0.294	
	Treatment	1.595	1.982	0.648	0.421	0.117
	Baseline	-0.690	0.089	59.481	**0.000**	
	SDS score	-0.091	0.382	0.057	0.812	
	Sex	1.173	2.606	0.203	0.653	
	Age	-0.110	0.096	1.305	0.253	
$CD4^{+}T$	Intercept	3.540	5.118	0.479	0.489	
	Treatment	1.101	1.222	0.812	0.368	0.131
	Baseline	-0.901	0.048	355.014	**0.000**	
	SDS score	-0.507	0.273	3.441	0.064	
	Sex	-0.322	1.180	0.075	0.785	
	Age	-0.064	0.053	1.445	0.229	
$CD8^{+}T$	Intercept	-10.415	4.383	5.646	**0.017**	
	Treatment	1.840	1.130	2.653	0.103	0.238
	Baseline	-0.942	0.047	394.806	**0.000**	
	SDS score	0.459	0.261	3.097	0.078	
	Sex	-0.266	1.053	0.064	0.801	
	Age	0.028	0.045	0.386	0.534	

CD, cluster of differentiation; NK, natural killer; p, p-value; SDS, severity of dependence scale.

Table S8. Anti-inflammatory drugs used by participants at least once during the trial.

Anti-inflammatory drugs, n (%)	Treatment group	
	CBD (n=24)	Placebo (n=24)
Inhaled corticosteroid	1 (4.2)	2 (8.3)
Topical corticosteroid	2 (8.3)	3 (12.5)
Nasal corticosteroid spray	2 (8.3)	0 (0.0)
Oral corticosteroid	0 (0.0)	0 (0.0)
Nonsteroidal anti-inflammatory drugs	3 (12.5)	3 (12.5)
Monoclonal antibody therapy	0 (0.0)	1 (4.2)
Total*	6 (25.0)	6 (25.0)

*Some participants took many anti-inflammatory drugs which explains why the total does not correspond to the sum. CBD, cannabidiol; n, number of participants.

Table S9. Sensitivity analysis without participants taking anti-inflammatory drugs.

Outcomes	Parameters	Estimate	Standard Error	Wald Chi square	p	Effect size
IL-6	Treatment	-0.392	0.165	5.674	**0.017**	0.347
	Treatment without participants taking anti-inflammatory drugs	-0.466	0.161	8.402	**0.004**	0.423
VEGF-A	Treatment	-14.417	6.722	4.600	**0.032**	0.313
	Treatment without participants taking anti-inflammatory drugs	-12.146	9.376	1.678	0.195	0.189
Intermediate monocytes ($CD14^{+}CD16^{+}$)	Treatment	-0.468	0.207	5.082	**0.024**	0.330
	Treatment without participants taking anti-inflammatory drugs	-0.258	0.213	1.470	0.225	0.177
NK $CD56^{neg}CD16^{hi}$	Treatment	-0.736	0.167	19.552	**0.000**	0.643
	Treatment without participants taking anti-inflammatory drugs	-0.673	0.182	13.682	**0.000**	0.539
$CD25^{+}CD4^{+}T$	Treatment	0.689	0.256	7.220	**0.007**	0.393
	Treatment without participants taking anti-inflammatory drugs	0.511	0.308	2.760	0.097	0.242

CD, cluster of differentiation; IL, interleukine; NK, natural killer; p, p-value; VEGF-A, vascular endothelial growth factor-A.

Table S10. Sensitivity analysis with anti-inflammatory drug use added as a binary covariate.

Outcomes	Parameters	Estimate	Standard Error	Wald Chi square	p	Effect size
IL-6	Intercept	-0.480	0.697	0.475	0.342	
	Treatment	-0.392	0.165	5.608	**0.018**	0.346
	Baseline	-0.993	0.094	111.527	**0.000**	
	SDS score	0.045	0.040	1.283	0.257	
	Sex	-0.347	0.244	2.024	0.155	
	Age	0.005	0.008	0.347	0.556	
	Anti-inflammatory drug use	0.023	0.240	0.009	0.923	
VEGF-A	Intercept	-47.149	33.890	1.936	0.164	
	Treatment	-14.462	6.792	4.535	**0.033**	0.311
	Baseline	-0.564	0.160	12.497	**0.000**	
	SDS score	0.025	1.254	0.000	0.984	
	Sex	-7.540	12.204	0.382	0.537	
	Age	0.342	0.339	1.018	0.313	
	Anti-inflammatory drug use	4.370	8.145	0.288	0.592	
Intermediate monocytes	Intercept	-0.006	1.024	0.000	0.996	
($CD14^{+}CD16^{+}$)	Treatment	-0.467	0.207	5.111	**0.024**	0.330
	Baseline	-0.554	0.124	19.946	**0.000**	
	SDS score	0.056	0.060	0.862	0.353	
	Sex	-0.097	0.297	0.107	0.744	
	Age	-0.017	0.010	2.984	0.084	
	Anti-inflammatory drug use	0.090	0.202	0.200	0.655	
NK $CD56^{neg}CD16^{hi}$	Intercept	-0.928	0.820	1.279	0.258	
	Treatment	-0.736	0.166	19.784	**0.000**	0.649
	Baseline	-0.427	0.073	34.490	**0.000**	
	SDS score	0.032	0.030	1.132	0.287	
	Sex	0.075	0.211	0.128	0.720	
	Age	0.004	0.012	0.096	0.757	
	Anti-inflammatory drug use	-0.074	0.158	0.218	0.641	
$CD25^{+}CD4^{+}T$	Intercept	-2.456	0.801	9.397	**0.002**	
	Treatment	0.685	0.259	6.999	**0.008**	0.386
	Baseline	-0.759	0.069	120.789	**0.000**	
	SDS score	0.035	0.051	0.467	0.494	
	Sex	0.164	0.366	0.202	0.653	
	Age	0.016	0.010	2.471	0.116	
	Anti-inflammatory drug use	-0.114	0.285	0.161	0.688	

CD, cluster of differentiation; IL, interleukine; NK, natural killer; p, p-value; SDS, severity of dependence scale; VEGF-A, vascular endothelial growth factor-A.

Table S11. Correlations between weight and inflammatory markers levels.

Inflammatory markers	Pearson r	t	df	p
IL-6	-0.060	-0.284	22	0.390
VEGF-A	-0.397	-2.029	22	**0.027**
Intermediate monocytes	-0.198	-0.949	22	0.177
NK $CD56^{neg}CD16^{hi}$	0.102	0.480	22	0.682
$CD25^{+}CD4^{+}T$	0.149	0.706	22	0.756

CD, cluster of differentiation; df, degree of freedom; IL, interleukine; NK, natural killer; p, p-value; r, correlation coefficient; t, Student t; VEGF-A, vascular endothelial growth factor-A.

Table S12. Correlations between cannabidiol plasma concentration and inflammatory markers levels.

Inflammatory markers	Pearson r	t	df	p
IL-6	-0.032	-0.148	22	0.442
VEGF-A	0.041	0.191	22	0.575
Intermediate monocytes	0.199	0.951	22	0.824
NK $CD56^{neg}CD16^{hi}$	-0.134	-0.634	22	0.266
$CD25^{+}CD4^{+}T$	-0.199	-0.954	22	0.175

CD, cluster of differentiation; df, degree of freedom; IL, interleukine; NK, natural killer; p, p-value; r, correlation coefficient; VEGF-A, vascular endothelial growth factor-A.

Table S13. Linear regressions analysis of inflammatory markers on drug-cue induced craving by treatment group.

Model	Variables	Estimate	Standard Error	t	p
IL-6	Intercept	3.498	3.621	0.966	0.340
	Treatment	-0.823	1.577	-0.522	0.604
	IL-6	0.838	0.887	0.944	0.351
	Baseline	-1.217	0.746	-1.632	0.111
	SDS score	-0.108	0.187	-0.576	0.568
	Sex	0.962	1.181	0.814	0.420
	Age	0.017	0.042	0.408	0.686
	Treatment*IL-6	1.118	0.980	1.140	0.261
VEGF-A	Intercept	4.550	3.689	1.233	0.225
	Treatment	2.383	2.753	0.865	0.392
	VEGF-A	-0.005	0.018	-0.308	0.760
	Baseline	0.014	0.015	0.947	0.349
	SDS score	-0.133	0.199	-0.669	0.508
	Sex	0.028	1.441	0.019	0.985
	Age	-0.008	0.047	-0.166	0.869
	Treatment*VEGF-A	-0.018	0.025	-0.728	0.471
Intermediate monocytes	Intercept	5.066	3.766	1.345	0.186
	Treatment	1.358	1.344	1.010	0.318
	Intermediate monocytes	0.218	0.484	0.451	0.655
	Baseline	0.339	0.515	0.658	0.514
	SDS score	-0.139	0.196	-0.708	0.483
	Sex	-0.053	1.353	-0.039	0.969
	Age	-0.016	0.046	-0.339	0.737
	Treatment*Intermediate monocytes	-0.398	0.803	-0.495	0.623
NK $CD56^{neg}CD16^{hi}$	Intercept	4.100	3.814	1.075	0.289
	Treatment	-0.140	1.808	-0.078	0.939
	NK $CD56^{neg}CD16^{hi}$	-0.362	0.925	-0.391	0.698
	Baseline	0.032	0.535	0.061	0.952
	SDS score	-0.114	0.205	-0.555	0.582
	Sex	0.739	1.241	0.595	0.555
	Age	0.009	0.045	0.196	0.845
	Treatment*NK $CD56^{neg}CD16^{hi}$	0.660	1.233	0.536	0.595
$CD25^{+}CD4^{+}T$	Intercept	3.345	4.000	0.836	0.408
	Treatment	1.231	1.764	0.698	0.489
	$CD25^{+}$ $CD4^{+}T$	-0.639	0.520	-1.230	0.226
	Baseline	0.523	0.355	1.475	0.148
	SDS score	-0.096	0.192	-0.499	0.620
	Sex	0.833	1.212	0.687	0.496
	Age	0.007	0.044	0.152	0.880
	Treatment*$CD25^{+}CD4^{+}T$	0.075	0.429	0.174	0.863

The dependent variable for all models was the difference between pre and post self-reported drug-cue induced craving scores (using a visual analogue scale ranging from 0 to 10). The five main significant inflammatory markers by treatment group were the independent variables in their respective model. Baseline inflammatory marker's level, SDS score, sex and age were added as covariates in all models. CD, cluster of differentiation; IL, interleukine; NK, natural killer; p, p-value; SDS, severity of dependence scale; t, Student t; VEGF-A, vascular endothelial growth factor-A.